Navigation Links
Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
Date:11/1/2012

SEATTLE, Nov. 1, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the first subject has been enrolled in the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.  OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.  This Phase 1 dose-ranging study is evaluating the drug's safety, tolerability and pharmacokinetics in healthy subjects, and Omeros expects clinical data before year end.

"We are excited that we have begun evaluating OMS824 – our first compound developed entirely in house – in humans," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.  "Our PDE10 program represents our fourth active clinical program, and the two in Phase 3 trials are poised to read out data this quarter.  We are also continuing to advance our preclinical pipeline, and currently three more programs are slated to enter the clinic in 2013."

About Omeros' PDE10 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition, including schizophrenia and Huntington's disease. Cognitive dysfunction occurs early in these diseases and is responsible for substantial disability. Omeros' proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders, including schizophrenia where OMS824 could also have a beneficial effect on the positive (e.g., hallucinations) and negative (e.g., flat affect) symptoms of the disease.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding when it will announce data from its Phase 1 clinical trial evaluating OMS824 as well as its two ongoing Phase 3 clinical programs; the number of preclinical programs that may enter the clinic in 2013; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2012. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
2. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
3. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
4. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
5. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
6. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
7. Synthetic Biologics Announces $10.8 Million Financing
8. Haemonetics Reports Second Quarter Fiscal 2013 Revenue Up 22%, Organic Revenue Up 6% and Adjusted EPS of $0.90, Reaffirms Fiscal 2013 Guidance and Announces Two-For-One Stock Split
9. Altogen Labs Announces Patent Filing for Bioremediation Process and Oil Spill Cleanup Products
10. Techne Corporation Declares Dividend And Announces An Increase In Its Share Repurchase Program
11. Law Office of Brodsky & Smith, LLC Announces Investigation of Complete Genomics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Aethlon Medical, Inc. (Nasdaq: AEMD ... validated the ability of the Aethlon Hemopurifier® to capture ... in immune-suppressed sepsis patients and also contribute to organ ... of the study was to validate the in ... and Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. ...
(Date:2/22/2017)... Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017 ... ) today announced its financial results for the ... "Our annual 2016 financial results reflect continued ... earnings exceeded $700 million," said Martine Rothblatt, Ph.D., ... financial results strengthen our ability to develop and ...
(Date:2/21/2017)... MENLO PARK, CA (PRWEB) , ... February 21, ... ... launch of the VTX-1 Liquid Biopsy System , a fully automated benchtop ... using microfluidic technology. The VTX-1 is being launched at the Molecular Medicine Tri ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... division, Treximo will pair its $200M operational capacity with its strategic internal ... management in areas affecting quality and operational management. With office locations ...
Breaking Biology Technology:
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
Breaking Biology News(10 mins):